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1) Overall survival (OS) results of a phase III 
randomized trial of standard-of-care therapy with or 
without enzalutamide for metastatic hormone-sensitive 
prostate cancer (mHSPC): ENZAMET (ANZUP 1304), 
an ANZUP-led international cooperative group trial.
Testosterone suppression (TS) is the backbone of treatment 
for metastatic hormone-sensitive prostate cancer (mHSPC). 
Overall survival is improved by the addition of early docetaxel 
(DOC) or abiraterone to TS. The randomised phase 3 EN-
ZAMET trial assessed the effects of enzalutamide (ENZA), a 
potent androgen receptor (AR) inhibitor, versus a nonsteroidal 
anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide) 
in addition to SOC in mHSPC.
Men (1125) with mHSPC were randomly assigned 1:1 
to receive TS plus either ENZA (160 mg daily, by mouth, 
until clinical disease progression or prohibitive toxicity) or 
NSAA (conventional NSAA, by mouth until clinical disease 
progression or prohibitive toxicity). All participants were 
to receive standard background therapy with a LHRHA or 
surgical castration, as per standard of care. The choice of the 
LHRHA or surgical castration was at the discretion of the 
treating clinician. Randomization was stratified by: volume 
of disease (high vs low, according to CHAARTED); planned 
early DOC; planned anti-resorptive therapy, comorbidity score 
(ACE-27), and study site. The primary endpoint was overall 
survival. Subgroup analyses to assess possible modulation 
of the treatment effect were specified a priori and included 
planned early docetaxel (yes vs no) and volume of disease 
(high vs low).
After a median follow-up of 33 months. Overall survival 
was prolonged by ENZA. At 3 years, 36% NSAA vs 64% 
ENZA were still on their assigned study treatment. Serious 
adverse events (regardless of attribution) within 30 days of 
study treatment occurred in 42% ENZA vs 34% NSAA, com-
mensurate with the different durations of study treatment.
ENZA significantly improved OS when added to SOC in 
mHSPC while the benefits appeared lower in those planned 
to receive early DOC. 
2) Results of enfortumab vedotin monotherapy for locally 
advanced or metastatic urothelial cancer previously 
treated with platinum and immune checkpoint inhibitors.
Locally advanced or metastatic urothelial cancer (la/
mUC) remains a lethal disease with limited treatment options 
for patients (pts) who progress on or after platinum and/or 
checkpoint inhibitor (CPI). Enfortumab vedotin (EV) is an 
antibody-drug conjugate targeting Nectin-4, which is highly 
expressed in UC. EV-201 is a pivotal, single-arm, two-cohort 
study of EV in la/mUC patients with prior CPI and platinum-
containing chemotherapy (Cohort 1) or a CPI and no prior 
chemotherapy (Cohort 2). Here, we present preliminary data 
from Cohort 1.
Patients in this open-label, multicenter study received 
1.25 mg/kg EV on Days 1, 8, and 15 of each 28-day cycle. 
The primary endpoint was confirmed overall response rate 
(ORR) per RECIST 1.1 by blinded independent central review. 
Secondary endpoints are duration of response, progression 
free survival (PFS), overall survival (OS), safety/tolerability. 
Between October 2017 and July 2018, EV-201 enrolled 
128 patient in Cohort 1 (la/mUC pts previously treated with 
platinum and a CPI), 125 of whom were treated with EV (70% 
male; median age 69 y [range 40–84 y]; 34% upper tract; a 
median of 2 prior systemic therapies). As of 03 January 2019, 
the confirmed ORR was 42% (95% CI: 33.6%–51.6%), with 
9% complete response (CR). The ORR in CPI non-respond-
ers was 38% (95% CI: 27.3%–49.2%), and 36% (95% CI: 
22.9%–50.8%) in patients with liver metastases (LM). Most 
common treatment-related adverse events (AEs), as determined 
by investigators, included fatigue (50%), alopecia (48%), and 
decreased appetite (41%). Treatment-related AEs of interest 
include any rash (48% all grade, 11% ≥G3) and any peripheral 
neuropathy (50% all grade, 3% ≥G3).
Preliminary results from this EV pivotal study demonstrated 
a clinically meaningful ORR, consistent with the phase 1 
trial, in la/mUC pts with prior platinum and CPI, including 
LM patients, where there is a high unmet need. EV was well 
tolerated with a manageable safety profile in these patients.
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3) MONALEESA-7: Addition of Ribociclib to Endocrine 
Therapy in Premenopausal Women with HR-Positive, 
HER2-Negative Breast Cancer
The phase III MONALEESA-7 study (NCT02278120) is 
the first trial to focus exclusively on women younger than age 
59 who were premenopausal and had advanced breast cancer 
for which they had not received prior endocrine therapy. 
Specifically, is the first dedicated trial of endocrine therapy 
(ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor 
in premenopausal patients with hormone receptor–positive 
(HR+)/HER2− ABC. The study met its primary endpoint 
of significantly longer progression-free survival (PFS) with 
ribociclib (RIB; a CDK4/6 inhibitor) + ET vs placebo (PBO) 
+ ET (median, 23.8 vs 13.0 mo; HR, 0.55; P< 0.0001.
A total of 672 women were enrolled in the study (N=672) 
with HR+/HER2− ABC. Investigators randomly assigned 
women to receive treatment with oral RIB or a PBO. All 
women enrolled also received goserelin, as injectable endocrine 
therapy, and one of three other therapies: the nonsteroidal 
aromatase inhibitors letrozole or anastrozole, or tamoxifen.
After a median follow-up of 34.6 months (min, 28.0 
months), 173 patients (26%) were still on treatment, with 116 
(35%) of them still receiving RIB and 57 (17%) still receiving 
PBO. Overall survival was evaluated after 192 deaths (83 in 
the RIB arm, 109 in the PBO arm). RIB + ET demonstrated a 
significantly longer OS than PBO + ET (HR, 0.712 [95% CI, 
0.54-0.95]; p = 0.00973). The result crossed the prespecified 
stopping boundary for superior efficacy. The researchers ob-
served that after 42 months of follow-up, for patients receiving 
RIB, the survival rate was 70% when given with ET, compared 
with 46% when given with PBO. In patients who received 
an NSAI (n=495), RIB + ET demonstrated a consistent OS 
improvement vs PBO + ET (HR, 0.699 [95% CI, 0.50-0.98]). 
Posttreatment therapy use was balanced between treatment 
arms—68.9% in the RIB arm and 73.2% in the PBO arm.
In this this phase III trial, RIB + ET demonstrated a clini-
cally and statistically significant longer OS than ET alone in 
premenopausal patients with HR+/HER2− ABC. This is the 
first time that a CDK4/6 inhibitor or any targeted agent + 
ET has demonstrated significantly longer OS vs ET alone as 
initial endocrine-based therapy.
4) KEYNOTE-062: Pembrolizumab With or Without 
Chemotherapy vs Chemotherapy in Advanced Gastric 
or GEJ Adenocarcinoma
The randomized, phase III KEYNOTE-062 trial achieved 
its primary endpoint, showing that for patients with pro-
grammed cell death ligand 1 (PD-L1)-positive (combined 
positive score ≥1, CPS ≥1), HER2-negative, advanced gastric 
or gastroesophageal junction (GEJ) cancer, initial therapy 
with pembrolizumab resulted in noninferior overall survival 
compared with standard chemotherapy. Additionally, pem-
brolizumab showed clinically meaningful improvement in 
overall survival among patients with tumors that had high 
levels of PD-L1 expression. At 2 years, 39% of patients who 
received pembrolizumab alone were alive, compared with 
22% of people who received standard chemotherapy. The 
trial also evaluated combined treatment with pembrolizumab 
and standard chemotherapy, and it found this regimen did not 
improve survival relative to chemotherapy alone. 
The investigators randomly assigned patients, in equal 
numbers, to receive Pembrolizumab 200 mg Q3W for up to 
2 years, Pembrolizumab+chemotherapy (cisplatin 80 mg/m2 
+ 5-FU 800 mg/m2/d on d1-d5 Q3W [or capecitabine 1000 
mg/m2 BID on d1-d14 Q3W per local guideline]) or placebo 
Q3W + chemotherapy. Randomization was stratified by region, 
disease status, and fluoropyrimidine treatment. Final analysis 
cutoff date was 26 March 2019. 
The trial enrolled 763 patients with a median age of 62 
years; 26% had previous gastric surgery to remove a tumor. 
In total, 69% had gastric cancer and 30% had GEJ cancer. 
Investigators focused on HER2-negative cancers alone, which 
studies have shown have a higher chance of recurrence after 
treatment, to limit factors that could affect outcomes. PD-L1 
expression was assessed via CPS. Previous studies of gastric 
or GEJ cancers have demonstrated that patients with a PD-L1 
CPS ≥1 may benefit from pembrolizumab, whereas a PD-L1 
CPS ≥10 or more indicates a higher likelihood of benefit. In the 
current trial, all patients had a PD-L1 CPS ≥1, and 281 (37%) 
of them had a PD-L1 CPS ≥10. From this pool of patients 257 
randomized to Pembrolizumab+Chemotherapy arm, 256 to 
Pembrolizumab and 250 to chemotherapy+placebo arm. The 
patients were followed for a median of 11.3 months. 
Pembrolizumab was noninferior to chemotherapy for 
overall survival in patients with CPS ≥1 per prespecified mar-
gins while it prolonged overall survival in CPS ≥10 patients 
(median 17.4 vs 10.8 months; HR 0.69; 95% CI 0.49-0.97). 
Pembrolizumab+chemotherapy vs chemotherapy was not su-
perior for overall survival in patients with CPS ≥1 or CPS ≥10, 
with a favorable trend for Pembrolizumab+chemotherapy arm. 
Pembrolizumab+chemotherapy did not significantly prolong 
progression free survival in CPS ≥1 group of patients. Overall 
response rate was higher for Pembrolizumab+chemotherapy 
arm vs chemotherapy one. The rates of serious side effects 
were lowest among patients treated with pembrolizumab alone. 
Grade 3 or higher toxic treatment-related adverse events were 
found in 17% of people receiving pembrolizumab, 73% of 
people receiving pembrolizumab and chemotherapy, and 69% 
of those receiving chemotherapy alone. The most common 
adverse events were nausea and fatigue.
In conclusion, Pembrolizumab was noninferior to chemo-
therapy for overall survival in patients with a CPS ≥1 with 
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clinically meaningful improvement for overall survival in 
CPS ≥10 group. Pembrolizumab+chemotherapy did not show 
superior overall survival and progression free survival in CPS 
≥1 and overall survival in CPS ≥10. The safety profile was 
more favorable for Pembrolizumab vs chemotherapy.
5) Docetaxel, trastuzumab, pertuzumab versus 
trastuzumab emtansine as neoadjuvant treatment  
of HER2-positive breast cancer: Results from  
the Swedish PREDIX HER2 trial identifying  
a new potential de-escalation standard?
Neoadjuvant therapy produces high rates of pathological 
complete response (pCR) and is the standard of care in HER2 
positive breast cancer; however, the optimal treatment regimen 
remains to be established.
In this randomized phase II study patients ≥18 years with 
HER2 positive breast cancer >20mm or verified lymph node 
metastases were randomized to 6 courses of docetaxel, trastu-
zumab and pertuzumab (DTP, group A/docetaxel 75-100 mg 
IV + trastuzumab 600 mg SC + pertuzumab 840 mg IV start-
ing dose, subsequently 420 mg IV) or trastuzumab emtansine 
(T-DM1, group B/trastuzumab emtansine 3.6 mg/kg IV), q 
21 days. The protocol allowed switch to the competing treat-
ment upon lack of response or drug-related severe toxicity. 
Patients received postoperative epirubicin+cyclophosphamide, 
trastuzumab for a total of one year and endocrine therapy. Ac-
crual was completed in October 2018 after randomization of 
202 patients, data on pCR were available for 190 at the time 
for this abstract submission. Median age, 52 years (26-74), 
menopausal status, histological type and grade were well 
balanced between the treatment groups. 62.6% of the tumors 
were hormone receptor (HR) positive.
Primary endpoint was pathological objective response. 
190 patients completed the protocol-specified preoperative 
treatment. pCR was achieved in 45.3% of patients, 46.4% in 
patients treated with DTP and 44.1% with T-DM1 (chi-sq., 
p=0.75). In HR-positive tumors, pCR was obtained in 35.3% 
of patients, 35.9% in group A vs. 34.6% in group B (p=0.87); 
in HR-negative tumors, the overall pCR rate was 62.0%, 
66.7% in group A vs. 57.9% in group B (p=0.45). Severe 
(grade 3/4) toxicity was reported at 68 occasions related to 
DTP, compared with 16 related to T-DM1, 26 vs. 3 caused 
by febrile neutropenia. Significantly better quality of life was 
reported by patients treated with T-DM1.
Data from PREDIX HER2 trial on TDM-1 demonstrates 
similar efficacy and less toxicity, in particular for patients 
with HER2 and HR positive cancers, being a potential new 
standard for neoadjuvant therapy.
6) SOPHIA primary analysis: A phase 3 study of 
margetuximab + chemotherapy versus trastuzumab + 
chemotherapy in patients with HER2+ metastatic breast 
cancer after prior anti-HER2 therapies
Pretreated HER2+ metastatic breast cancer lacks a defined 
standard of care, although trastuzumab is commonly used. 
Margetuximab has similar HER2 binding and antiproliferative 
effects as trastuzumab. By contrast, margetuximab’s Fc region 
is engineered to increase affinity for both alleles of the activat-
ing Fc receptor (FcR), CD16A, and decrease affinity for the 
inhibitory FcR, CD32B. The low affinity CD16A-158F allele 
(~85% of population) has been associated with diminished 
clinical response to trastuzumab. In a Phase 1 trial, margetuxi-
mab demonstrated acceptable safety, anti-tumor activity, and 
evidence of HER2-specific antibody and T-cell responses.
SOPHIA (NCT02492711), a randomized, open-label Phase 
3 trial, enrolled patients with HER2+ metastatic breast cancer 
after pertuzumab and 1–3 lines of prior anti-HER2 therapies for 
breast cancer. Patients were randomized 1:1 to margetuximab 
(15 mg/kg IV q3w + chemotherapy) or trastuzumab (6 [8 for 
loading dose] mg/kg IV q3w + chemotherapy), stratified by 
met sites (≤2, >2), lines of trastuzumab for met disease (≤2, 
>2), and chemotherapy choice (standard dose capecitabine, 
eribulin, gemcitabine, or vinorelbine). Primary endpoints are 
central blinded progression free disease (PFS) and overall sur-
vival (OS), assessed sequentially using the stratified log-rank 
test. Objective response rate (ORR) was a secondary endpoint. 
257 PFS events were required to provide 90% power to show 
PFS superiority at 2-sided α = 0.05.
Intent-to-treat analysis (536 patients: margetuximab 266; 
trastuzumab 270) occurred after 265 PFS events. Margetuximab 
prolonged PFS over trastuzumab (median 5.8 vs 4.9 months, 
hazard ratio [HR], 0.76; 95% CI, 0.59–0.98; P= 0.033). Treat-
ment effects were more pronounced in patients with CD16A 
genotypes containing a 158F allele (median PFS 6.9 vs 5.1 
months, HR, 0.68; 95% CI, 0.52–0.90; P= 0.005). In 524 
patients with baseline measurable disease (margetuximab 
262; trastuzumab 262), ORR was higher with margetuximab 
(22%; 95% CI, 17.3-27.7%) vs trastuzumab (16%; 95% CI 
11.8-21.0%). Safety profiles were comparable in 529 patients 
who received study therapy. Grade ≥3 AEs and serious AEs 
occurred in 138 (52%) and 39 (15%) vs 128 (48%) and 46 
(17%) patients on margetuximab vs trastuzumab, respectively. 
In combination with chemotherapy in pretreated HER2+ 
metastatic breast cancer, margetuximab improves PFS over 
trastuzumab with comparable safety. CD16A genotyping 
suggests a differential benefit in patients with a 158F allele. 
OS data are maturing.
